Impact of Ga68-DOTATOC PET/MRI on Therapy Management in Patients with Neuroendocrine Neoplasia (NEN) - Preliminary Results

#2882

Introduction: Integrated PET/MRI combines the sensitivity and functional relevance of PET imaging and the spatial resolution and soft tissue contrast of MRI.

Aim(s): To evaluate the influence of the submodalities of 68Ga-DOTATOC PET/MRI on therapeutic strategy in patients with known or suspected neuroendocrine neoplasms (NEN).

Materials and methods: 80 patients with histologically confirmed (68) or suspected (12) NEN (34 f; age 66 [29-82] y) received PET/MRI between February 2017 and April 2019. PET and contrast enhanced MRI were separately evaluated in consensus by two independent blinded readers. Results were presented during simulated tumor boards, and the respective strategy was compared with the original decision based on hybrid PET/MRI made by the institutional tumor board. Impact of submodalities was tested with the McNemar test.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Amthauer H

Authors: Radojewski P, Nagel S, Fehrenbach U, Jann H, Rogasch J,

Keywords: PET/MRI, 68Ga-DOTATOC, neuroendocrine neoplasm, therapeutic strategy,